Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGYP
  • CUSIP: 87163930
  • Web:
  • Market Cap: $602.88 million
  • Outstanding Shares: 224,954,000
Average Prices:
  • 50 Day Moving Avg: $3.07
  • 200 Day Moving Avg: $4.01
  • 52 Week Range: $2.57 - $7.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.41 million
  • Price / Sales: 249.22
  • Book Value: $0.19 per share
  • Price / Book: 14.05
  • EBIDTA: ($216,830,000.00)
  • Return on Equity: -485.02%
  • Return on Assets: -202.73%
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 2.33%
  • Quick Ratio: 2.07%
  • Average Volume: 4.48 million shs.
  • Beta: 1058.95
  • Short Ratio: 21.18

Frequently Asked Questions for Synergy Pharmaceuticals (NASDAQ:SGYP)

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.08. The firm had revenue of $2.31 million for the quarter, compared to analysts' expectations of $1.98 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. View Synergy Pharmaceuticals' Earnings History.

Where is Synergy Pharmaceuticals' stock going? Where will Synergy Pharmaceuticals' stock price be in 2017?

10 brokerages have issued 12 month price objectives for Synergy Pharmaceuticals' stock. Their forecasts range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $9.60 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.

What are analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (9/13/2017)
  • 2. HC Wainwright analysts commented, "We note that the launch of Trulance appears to be progressing on multiple fronts, with the company having reached 66% of its targeted prescriber base and over 90% of the high-volume prescribers (deciles 8-10). According to QuintilesIMS data, as of mid-2017 over 12,600 Trulance prescriptions had been filled and total monthly prescription volume has increased on average over 182% month-over-month during that period. Over 32% of all high prescribers had written a Trulance prescription since the drug was launched earlier this year, with an average increase for all prescribers of approximately 140% month-over-month. Trulance achieved 6.8% new-to-brand prescription (NBRx) total market share and 12% NBRx market share among gastroenterologists. Importantly, about 55% of new Trulance prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment and 45% were patients who converted from other branded prescription treatments." (8/10/2017)
  • 3. Cantor Fitzgerald analysts commented, "Management upbeat about early returns. SGYP reported 2Q17 results and posted a new corporate presentation to provide an update of the Trulance launch (here). We spoke with management (no results call was held) to hear its views regarding how the launch is proceeding. Acknowledging the inherent positive bias of company managements that have launched their inaugural product, we believe metrics provided by SGYP may, however, show an objective snapshot of the launch." (8/10/2017)
  • 4. BTIG Research analysts commented, "With the US launch of Trulance (3 mg plecanatide, for the treatment of chronic constipation) now officially underway, investor focus now turns to the ramp for Trulance in the US market. We continue to believe management is up to the task of successfully launching Trulance via its hybrid sales model (utilizing an experienced contract sales force of ~150 - 200 reps), which is expected to target ~27,000 high-prescribing physicians. While we believe formulary access for Trulance could take up to 6 months, we think most insurance plans will put Trulance on a Tier 3 co-pay, with the Co. offering its 'savings to go' program as an offset. Our channel checks with several local pharmacies in NYC this morning suggest that this program will enable patients to get access to Trulance at a much lower cost (no more than $25 per Rx). Management also recently highlighted at an investor conference earlier today that a nationwide sampling program is underway. In sum, we expect the launch of Trulance to lead to more patients switching from OTC laxatives to Rx treatments, with Trulance leading to an expansion of the overall Rx market." (3/21/2017)

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 67,570,644 shares, an increase of 6.8% from the August 15th total of 63,271,755 shares. Based on an average trading volume of 2,888,418 shares, the short-interest ratio is currently 23.4 days. Currently, 30.1% of the shares of the company are short sold.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:

  • Gary S. Jacob Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Gary G. Gemignani, Chief Financial Officer, Executive Vice President
  • Marino Garcia, Executive Vice President, Chief Strategy Officer
  • Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer
  • Troy Hamilton, Executive Vice President, Chief Commercial Officer
  • Melvin K. Spigelman M.D., Lead Independent Director
  • Thomas H. Adams Jr. Ph.D., Independent Director
  • John P. Brancaccio CPA, Independent Director
  • Timothy S. Callahan, Independent Director
  • Richard J. Daly, Independent Director

Who owns Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.75%), State Street Corp (5.75%), Northern Trust Corp (1.25%), TimesSquare Capital Management LLC (1.14%), Pictet Asset Management Ltd. (0.89%) and JPMorgan Chase & Co. (0.88%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Who sold Synergy Pharmaceuticals stock? Who is selling Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., TIAA CREF Investment Management LLC, Palisade Capital Management LLC NJ, Bank of New York Mellon Corp, Cambridge Investment Research Advisors Inc., D.A. Davidson & CO. and State Treasurer State of Michigan. View Insider Buying and Selling for Synergy Pharmaceuticals.

Who bought Synergy Pharmaceuticals stock? Who is buying Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., OxFORD Asset Management LLP, JPMorgan Chase & Co., Northern Trust Corp, Hikari Power Ltd, State Street Corp, Virtu KCG Holdings LLC and Pictet Asset Management Ltd.. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy Synergy Pharmaceuticals stock?

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $2.67.

MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  540
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Synergy Pharmaceuticals (NASDAQ:SGYP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.60 (259.55% upside)

Analysts' Ratings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/13/2017Citigroup Inc.Reiterated RatingSell -> Sell$3.20 -> $2.50MediumView Rating Details
9/8/2017BTIG ResearchReiterated RatingBuy$11.00MediumView Rating Details
9/8/2017CIBCLower Price TargetOutperform -> Outperform$9.00 -> $6.00LowView Rating Details
9/8/2017Cantor FitzgeraldReiterated RatingOverweight$11.00MediumView Rating Details
9/8/2017Oppenheimer Holdings, Inc.Lower Price TargetOutperform$9.00 -> $6.00MediumView Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy -> Buy$18.00 -> $15.00HighView Rating Details
8/10/2017HC WainwrightSet Price TargetBuy$15.00HighView Rating Details
7/31/2017Canaccord GenuitySet Price TargetBuy$13.00LowView Rating Details
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/AView Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Earnings History by Quarter for Synergy Pharmaceuticals (NASDAQ SGYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.25)($0.33)$1.98 million$2.31 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.23)($0.30)$0.10 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.20)($0.31)ViewN/AView Earnings Details
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)
2017 EPS Consensus Estimate: ($0.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for Synergy Pharmaceuticals (NASDAQ:SGYP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 71.47%
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/7/2017Paulson & Co. Inc.Major ShareholderSell26,287$3.77$99,101.99View SEC Filing  
5/26/2017Gary S JacobCEOBuy5,680$3.52$19,993.60View SEC Filing  
5/26/2017John P BrancaccioDirectorBuy6,500$3.59$23,335.00View SEC Filing  
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.68View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Synergy Pharmaceuticals (NASDAQ:SGYP)
Latest Headlines for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateHeadline logoSynergy Pharmaceuticals, Inc. (SGYP) Short Interest Update - September 14 at 1:46 AM logoZacks Investment Research Upgrades Synergy Pharmaceuticals, Inc. (SGYP) to "Hold" - September 13 at 8:32 PM logoSynergy Pharmaceuticals, Inc. (SGYP) Price Target Cut to $2.50 by Analysts at Citigroup Inc. - September 13 at 6:04 PM logoSynergy Pharmaceuticals (SGYP) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 13 at 9:04 AM logoSynergy: A Trek Worth Taking - Seeking Alpha - September 13 at 9:04 AM logoSynergy Pharmaceuticals, Inc. (SGYP) to Post FY2017 Earnings of ($1.20) Per Share, Cantor Fitzgerald Forecasts - September 13 at 8:30 AM logoSynergy Pharmaceuticals' (SGYP) CEO Gary Jacob on Business Update Call (Transcript) - Seeking Alpha - September 9 at 8:29 AM logoEdited Transcript of SGYP earnings conference call or presentation 7-Sep-17 8:30pm GMT - September 9 at 8:29 AM logoSynergy Pharmaceuticals' (SGYP) Buy Rating Reiterated at BTIG Research - September 9 at 12:32 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Rating Reiterated by Cantor Fitzgerald - September 8 at 6:44 PM logoCIBC Trims Synergy Pharmaceuticals, Inc. (SGYP) Target Price to $6.00 - September 8 at 2:32 PM logoOppenheimer Holdings, Inc. Trims Synergy Pharmaceuticals, Inc. (SGYP) Target Price to $6.00 - September 8 at 10:46 AM logoSynergy Pharmaceuticals to Present at Upcoming September Investor Conferences - September 7 at 8:55 AM logoSynergy Pharma (SGYP) Closes $300M Debt Financing; to Fund Current Plans Through 2019 - September 6 at 8:15 AM logoSynergy Pharma: It Takes Money To Make Money - Seeking Alpha - September 6 at 8:15 AM logoSynergy Pharmaceuticals Secures $300 Million Debt Financing - September 6 at 8:15 AM logo2017 is a Transformative Year for Synergy, Q2 Review, and Analyst Outlook - September 6 at 8:15 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Cut to Strong Sell at ValuEngine - September 2 at 3:04 PM logoSynergy Pharmaceuticals: Risky But Still A Buy - Seeking Alpha - August 30 at 9:11 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Receives Average Recommendation of "Hold" from Brokerages - August 29 at 9:16 PM logoSynergy Pharmaceuticals, Inc. (SGYP) Sees Large Increase in Short Interest - August 26 at 1:48 AM logoSynergy's Festering Issue - Seeking Alpha - August 25 at 9:07 PM logoSynergy Pharmaceuticals: A Hidden Gem In The BioPharma Sector - August 16 at 7:26 AM logoOppenheimer Holdings Brokers Cut Earnings Estimates for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - August 14 at 2:06 AM logoSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Expected to Announce Quarterly Sales of $6.50 Million - August 12 at 1:34 PM logoSynergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : August 12, 2017 - August 12 at 7:47 AM logoSynergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : August 12, 2017 - August 12 at 7:47 AM logoFY2021 EPS Estimates for Synergy Pharmaceuticals, Inc. Decreased by Oppenheimer Holdings (NASDAQ:SGYP) - August 11 at 5:22 PM logoIHS Markit Score Update: Drop in demand for ETFs holding Synergy Pharmaceuticals Inc is a negative sign for its shares - August 11 at 8:27 AM logoHere's Why Synergy Pharmaceuticals Inc. Is Falling Today - August 11 at 8:27 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Price Target Cut to $15.00 - August 10 at 9:08 AM logo Brokerages Expect Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Will Post Earnings of -$0.22 Per Share - August 10 at 8:06 AM logoSynergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update - August 10 at 7:52 AM logoInsider Selling: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Major Shareholder Sells 26,287 Shares of Stock - August 9 at 9:28 PM logoSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Announces Quarterly Earnings Results - August 9 at 9:20 PM logoSynergy Pharmaceuticals Inc. Tanked 14.2% in July -- but Why? - August 9 at 7:25 AM logoBidaskClub Downgrades Synergy Pharmaceuticals, Inc. (SGYP) to Strong Sell - August 5 at 5:30 PM logoA More Realistic Outlook For Synergy Pharmaceuticals - Seeking Alpha - August 5 at 7:02 AM logoA More Realistic Outlook For Synergy Pharmaceuticals - Seeking Alpha - August 5 at 7:02 AM logoSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Given Average Rating of "Hold" by Brokerages - August 4 at 8:44 PM logoSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Downgraded by BidaskClub to "Sell" - July 29 at 12:54 PM logoSynergy Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SGYP-US : July 28, 2017 - July 29 at 7:13 AM logoETFs with exposure to Synergy Pharmaceuticals, Inc. : July 25, 2017 - July 26 at 7:20 AM logoETFs with exposure to Synergy Pharmaceuticals, Inc. : July 24, 2017 - July 25 at 6:39 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Expected to Announce Quarterly Sales of $2.62 Million - July 22 at 8:00 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Expected to Post Earnings of -$0.22 Per Share - July 20 at 10:18 PM logoOppenheimer Holdings, Inc. Reaffirms Outperform Rating for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - July 18 at 12:36 PM logoSynergy Pharmaceuticals, Inc. (SGYP) Rating Lowered to Sell at Zacks Investment Research - July 18 at 9:28 AM logoQ3 2017 EPS Estimates for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Lowered by Analyst - July 17 at 8:11 AM logoETFs with exposure to Synergy Pharmaceuticals, Inc. : July 14, 2017 - July 15 at 8:32 AM



Synergy Pharmaceuticals (SGYP) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff